Business Context and Reporting Period
This Form 8-K was filed by Aerpio Pharmaceuticals, Inc. on May 22, 2018. The filing reports a corporate event under Item 8.01 (Other Events) regarding the advancement of its drug development pipeline. Note: The request metadata references "Whitehawk Therapeutics, Inc.," but the filing text explicitly identifies the registrant as Aerpio Pharmaceuticals, Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report focused on a specific operational milestone rather than a financial statement.
Material Changes
The material change reported is the initiation of dosing in a Phase 1a, multiple-ascending dose clinical study for AKB-4924. This investigational drug is a Hypoxia-Inducible Factor-1 Alpha (HIF-1α) stabilizer being developed for the treatment of Inflammatory Bowel Disease (IBD).
Guidance, Outlook, and Risks
Management Commentary: The company issued a press release (Exhibit 99.1) announcing the start of the Phase 1a study, signaling progress in its clinical development program for IBD.
Risks and Contingencies: The filing does not explicitly detail new risks or contingencies beyond the inherent uncertainties of clinical trials. As an emerging growth company, the registrant has elected not to use the extended transition period for complying with new or revised financial accounting standards.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for detailed study design and enrollment targets.
- Confirm the current cash runway and funding status in the most recent 10-Q or 10-K, as this 8-K contains no financial data.
- Monitor future filings for data readouts from the Phase 1a study of AKB-4924.
- Check for any subsequent updates regarding the company's status as an emerging growth company.